Related Experiment Video
Updated: Jan 23, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
Risk of hypertension in cancer patients treated with abiraterone: a meta-analysis
Xiaolei Zhu1, Shenhong Wu2,3
11Division of Primary Care, State University of New York at Stony Brook, 205 North Belle Mead Road, East Setauket, Stony Brook, NY 11733 USA.
Background:
Hypertension is one of the major side effects associated with abiraterone in the treatment of advanced prostate cancer. The specific contribution of abiraterone to hypertension has not been defined. We performed a systematic review and meta-analysis of randomized clinical trials to determine its overall risk.
Methods:
Databases including Pubmed (up to July 2018) and Google scholar (up to July 2018) were searched to identify relevant studies. Eligible studies were prospective randomized clinical trials with prostate cancer treated with abiraterone and prednisone. The incidence and relative risk (RR) of hypertension was calculated using random-effects or fixed-effects model depending on the heterogeneity of included studies.
Results:
A total of five studies including 5445 patients were selected for analysis. Among patients receiving abiraterone, the overall incidences of all grade and high grade (grade 3 and 4) were 21.9% (95% CI: 13.6-33.2%) and 10.2% % (95% CI: 6.9-11.6%). Abiraterone was associated with a significantly increased risk of hypertension of all grade with a relative risk of 1.80 (95% CI: 1.47-2.19%, p < 0.001) and high grade with a relative risk of 2.11 (95%CI: 1.66-2.68%, p < 0.001) in comparison with controls. The risk of hypertension may be affected by concurrent use of prednisone with 5 mg daily is associated with higher incidence than that of prednisone 5 mg twice daily (32.4% vs 16.5%).
Conclusion:
There is a significant increase of developing hypertension in prostate cancer patients treated with abiraterone. Appropriate monitoring and management is strongly recommended to reduce the risk of cardiovascular events and treatment interruptions.
More Related Videos
04:34Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
Published on: February 17, 2023
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Related Concept Videos
Directing Effect of Substituents: meta-Directing Groups
Cancer Survival Analysis
Relative Risk
Hypertension I: Introduction
Hypertension II: Pathophysiology
Hypertension V: Nursing Management